Month: January 2016

Local Kent company based in Harrietsham – Bedfont Scientific Ltd – has now released its video as part of the campaign to compete for ‘National Public Champion’ in this year’s European Business Awards and they need your votes!

Bedfont Scientific, based in Harrietsham, Kent, has posted a video explaining why you should vote for them on its website at www.bedfont.com, giving a powerful insight into the story of the business and its success. In 2016, the company is celebrating two important anniversaries – 40 years in business and 30 years of one of their most successful exports – the Smokerlyzer.  Revered as pioneers in the breath analysis market, their products are now available, in over 70 countries across the world with an unprecedented network of appointed distributors.

The European Business Awards was created to recognise and promote business success and support the development of a stronger business community throughout Europe. 

Competing against all other country National Champions for the public vote, the company with the most votes will be named ‘National Public Champion’ for the UK on 7th March 2016. The first phase of the online voting is open from 11 January to 26 February 2016. 

Trevor Smith, Managing Director at Bedfont, says:

“We are grateful for the opportunity to show the people of Kent what our business does and how we save lives. We are encouraging people to vote online for us once they have viewed our video. The public vote means a great deal as it’s not just our existing and potential customers giving their approval to our success but also all the people we’ve helped in our 40 years of business.”

Adrian Tripp, CEO of the European Business Awards, said,

“Last year the public vote generated over 170,000 votes from across the world.  It is a very important part of the Awards as it gives these entrepreneurial companies another way of showcasing their achievements.”

Bedfont Scientific Ltd based in Harrietsham, Kent, aims to expand its Gastrolyzer range across the UK and Ireland with the help of new distributor Kebomed.

Bedfont Scientific, a leading manufacturer of exhaled breath monitors, are proud to introduce Kebomed as the new distributor for its Gastrolyzer range throughout the United Kingdom and Ireland. Kebomed will become the 74th member of Bedfont’s exclusive diagnostics distributor network; a structure which has led to much success for Bedfont.

The Gastrolyzer range uses breath analysis to measure levels of Methane, Hydrogen and Oxygen and can accurately detect a range of gastrointestinal (GI) disorders such as Small Intestinal Bacterial Overgrowth (SIBO) or food intolerances such as lactose or fructose intolerance. The Gastrolyzer range is also commonly used in the investigation of Irritable Bowel Syndrome (IBS), a disorder which affects 23 per cent of people worldwide. The success of the Gastrolyzer range is due to the innovative way in which it can help detect GI disorders; its non-invasive manner and instant results are unlike more traditional methods which can take up to two weeks to diagnose.

Matthew Skinner, Gastrolyzer Product Manager at Bedfont, says,

“We always welcome the opportunity to start new collaborations with new distributors; Kebomed have the knowledge of the industry and share our belief in the importance of Gastrointestinal services. We welcome Kebomed into our fold and hope that this new relationship helps us to further strengthen our coverage of the Gastrolyzer range throughout the United Kingdom and Ireland”.

Pardeep Rai, GI Sales Director at Kebomed, says, 

“We aim to use our knowledge of the GI market to increase the Gastrolyzer’s portfolio in the UK and Ireland, and look forward to this opportunity leading to growth for both companies”.  

Bedfont Scientific Limited has created a subsidiary as part of its long term development and expansion plans. The new company NOxBOX Limited will concentrate on its hugely successful range of Inhaled Nitric Oxide monitoring systems.

Bedfont Scientific Limited, established in 1976 in Harrietsham, Kent, specialises in exhaled breath and gas monitors which are used in the medical industry. The NOxBOX range was introduced by Bedfont in 1992 and is used to deliver and monitor inhaled nitric oxide (iNO) therapy.

iNO therapy is mainly used in intensive care units (ICU) to aid in the therapeutic care of premature babies and patients under severe respiratory distress. Using iNO therapy allows the blood supply to pick up oxygen from the lungs more readily by dilating the pulmonary arteries, making it the ideal method of treatment for pulmonary hypertension and other conditions that can lead to severe breathing difficulties. It is also the only iNO therapy monitor that can be used during transport, making it ideal for ambulances.

The new subsidiary company will focus on increasing awareness of the NOxBOX product and associated healthcare benefits to improve market share in the UK, Europe and further develop its customer base across the global market, while its parent company Bedfont Scientific will concentrate on developing new products and increasing use of its wide range of existing breath and gas monitoring systems.

Jason Smith, Bedfont Scientific’s General Manager, says,

“The success of the NOxBOX range has led us to what we feel is a natural progression that will further ensure the continued high levels of quality and service for our customers.

“Our aim for NOxBOX Limited is to grow the customer base globally, continuing to save lives, one breath at a time.”